You are viewing the site in preview mode
Skip to main content
| |
EA, n = 28
|
nEA, n = 31
|
EC, n = 29
|
nEC, n = 30
|
p-value
|
|---|
|
EA vs. nEA
|
EA vs. EC
|
nEA vs. nEC
|
EC vs. nEC
|
|---|
|
Women, n/N (%)
|
17/28 (60.71%)
|
19/31 (61.29%)
|
22/29 (75.9%)
|
19/30 (63.3%)
|
ns
|
ns
|
ns
|
ns
|
|
Age years, mean ± SD
|
71 ± 5.4
|
39.5 ± 5.8
|
70.4 ± 4.8
|
35.7 ± 5.5
|
< 0.001
|
ns
|
ns
|
< 0.001
|
|
Atopy, n/N (%)
|
13/27 (48.15%)
|
22/25 (88%)
|
10/29 (34.5%)
|
14/29 (48.3%)
|
0.002
|
ns
|
0.001
|
ns
|
|
BMI, median (25–75%)
|
28.7 (25.3–32.1)
|
25.4 (20.5–29.3)
|
26 (24.2–28.5)
|
24.2 (21.9–27.7)
|
ns
|
ns
|
ns
|
ns
|
|
BMI > 25, n/N (%)
|
23/28 (82.1%)
|
17/31 (54.8%)
|
16/29 (55.2)
|
11/30 (36.7%)
|
ns
|
ns
|
ns
|
ns
|
|
FEV1%pred. val., median (25–75%)
|
90.7 (74.8–104.1)
|
94.7 (86–107.7)
|
104.4 (99.1–115.9)
|
110.6 (103.7–113.8)
|
ns
|
0.007
|
0.049
|
ns
|
|
FEV1%/FVC, mean ± SD
|
88.4 ± 20.9
|
94.8 ± 15.1
|
106.5 ± 14.7
|
106.9 ± 17.7
|
ns
|
0.002
|
< 0.001
|
< 0.001
|
|
R5Hz %pred. value, median (25–75%)
|
135 (95.1–173.2)
|
111.4 (97.1–142.9)
|
90.4 (72–115.9)
|
96.8 (88.6–108.8)
|
ns
|
0.003
|
0.046
|
ns
|
|
δR5–R20% pred., median (25–75%)
|
32 (16.5–55.9)
|
20.3 (7.6–34.4)
|
18.5 (10.1–26.7)
|
10.8 (1.8–17.7)
|
ns
|
ns
|
ns
|
ns
|
|
δR5–R20 > 20%, n/N (%)
|
20/27 (74.07%)
|
16/31 (51.61%)
|
13/28 (53.6%)
|
0/30 (0%)
|
ns
|
ns
|
0.009
|
0.03
|
|
FeNO, ppb, median (25–75%)
|
22.8 (19.5–28)
|
20 (14.5–32)
|
21.8 (18.3–28.5)
|
18.5 (14.5–22)
|
ns
|
ns
|
ns
|
ns
|
|
FeNO > 25 ppb n/N (%)
|
11/26 (42.3%)
|
12/31 (38.7%)
|
10/28 (35.7%)
|
3/29 (10.3%)
|
ns
|
ns
|
ns
|
ns
|
|
ACT, median (25–75%)
|
21 (17–25)
|
22 (19–25)
|
–
|
–
|
ns
|
–
|
–
|
–
|
|
ACT < 20 score, n/N (%)
|
11/27 (40.74%)
|
9/31 (29.03%)
|
–
|
–
|
ns
|
–
|
–
|
–
|
|
Uncontrolled Asthma according to GINA 2017, n/N (%)
|
8/27 (29.6%)
|
4/31 (12.9%)
|
–
|
–
|
ns
|
–
|
–
|
–
|
|
Severe asthma according to GINA 2017, n/N (%)
|
15/28 (53.6%)
|
16/31 (51.6%)
|
–
|
–
|
ns
|
–
|
–
|
–
|
|
Patients with exacerbation/last year, n/N (%)
|
19/28 (67.9%)
|
11/31 (35.5%)
|
–
|
–
|
0.012
|
–
|
–
|
–
|
|
Number of comorbidities, median (25–75%)
|
7 (4–8.5)
|
3 (1–3)
|
3 (2–5)
|
0 (0–1)
|
< 0.001
|
0.02
|
< 0.001
|
< 0.001
|
- Normally distributed data are presented as mean ± standard deviation, and analysed by Student’s t-test. Non-normally distributed data are presented as median and 25–75% percentile (in parentheses). Data are compared between age groups using the Mann–Whitney test or Kruskal–Wallis test followed by Dunn’s Multiple comparison test. χ2 test was used for testing relationships between categorical variables
- Bold text indicates a statistically significant p-value
- EA elderly asthmatics, nEA non-elderly asthmatics, EC elderly controls, nEC non-elderly controls, SI systemic inflammation, IOS impulse oscillometry, FeNO fractional exhaled nitric oxide, SPTs skin prick tests, ACT Asthma Control Test, FEV1% pred. forced expiratory volume in one second % of predicted value, FEV1%FVC forced expiratory volume in one second/forced vital capacity ratio, R5Hz% pred. resistance at 5 Hz, % of predicted value, δR5–20 Hz difference of resistance at 5 and 20 Hz, PBMCs peripheral blood mononuclear cells, BMI body mass index
